Table 2.
Distribution of socio-demographic and clinical features in 9 OPSCC patients who recurred within 24 months from end of treatment (cases) and 24 OPSCC patients who did not (controls) who served as validation set
| Variable | Cases, n = 9 | Controls, n = 24 | p valuec | ||
|---|---|---|---|---|---|
| n | (%) | n | (%) | ||
| Gender | |||||
| Male | 4 | (44.4) | 17 | (70.8) | 0.23 |
| Female | 5 | (55.6) | 7 | (29.2) | |
| Age, years | |||||
| <55 | 1 | (11.1) | 4 | (16.7) | 1.00 |
| 55–59 | 2 | (22.2) | 4 | (16.7) | |
| ≥60 | 6 | (66.7) | 16 | (66.7) | |
| Smoking habits | |||||
| Never | 3 | (33.3) | 5 | (20.8) | 0.32 |
| Former | 1 | (11.1) | 1 | (4.2) | |
| Current | 5 | (55.6) | 18 | (75.0) | |
| Na, b | |||||
| 0–1 | 3 | (33.3) | 9 | (37.5) | 1.00 |
| 2–3 | 6 | (66.7) | 15 | (62.5) | |
| Ta, b | |||||
| 1–2 | 3 | (33.3) | 8 | (33.3) | 1.00 |
| 3–4 | 6 | (66.7) | 16 | (66.7) | |
| Stage | |||||
| III | 2 | (22.2) | 6 | (25.0) | 1.00 |
| IV | 7 | (77.8) | 18 | (75.0) | |
| HPV16 | |||||
| Negative | 8 | (88.9) | 12 | (50.0) | 0.06 |
| Positive | 1 | (11.1) | 12 | (50.0) | |
| Therapy | |||||
| RT ± CT | 3 | (33.3) | 12 | (50.0) | 0.46 |
| RT + CH ± CT | 6 | (66.7) | 12 | (50.0) | |
aThe sum does not add up to total because of missing values
b N number of lymph nodes involved, T tumor size, RT radiotherapy, CT chemotherapy, CH surgery
cFisher’s exact test
dStatistical comparison of the different characteristics in discovery and validation series